TABLE 3.
Clone | BILN 2061 |
% remaining wild type (mutation[s])c |
||||||
---|---|---|---|---|---|---|---|---|
Genotype | Conc/nMa | Day | Position | WTb | Replicate 1 | Replicate 2 | Control | |
J1b1b | 1b | 230 | 8 | 168 | D | 0 (7G, 1A, 1E, 1V) | 10 (3G, 1A, 5E) | 100 |
156 | A | 60 (4V) | 90 (1V) | 100 | ||||
J2a2a-T1066S | 2a | 1,000 | 22 | 168 | D | 0 (8V, 2Y) | 0 (4V, 6Y) | 100 |
195 | Q | 100 | 40 (6H) | 100 | ||||
J3a3a | 3a | 7,000 | 21 | 168 | Q | 0 (4L, 5R, 1K) | 0 (8L, 2K) | 100 |
J4a4a-19 | 4a | 100 | 13 | 168 | D | 20 (6G, 2V) | 20 (4G, 2A, 2E) | 100 |
156 | A | 80 (2V) | 80 (2T) | 100 | ||||
J5a5a-Q1240L | 5a | 500 | 21 | 168 | E | 0 (7A, 1V, 2G) | 10 (9A) | 100 |
J6a6a | 6a | 10 | 28 | 168 | D | 30 (4V, 2E, 1H) | 30 (3V, 1E, 3N) | 100 |
Final passage concentration of BILN 2061.
WT, wild type.
Proportion of clones retaining the original amino acid results from two replicate passage experiments (10 clones analyzed in each) and in a control passaged without BILN 2061 (10 clones analyzed).